Patents by Inventor Antara Banerjee

Antara Banerjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof
    Patent number: 12202901
    Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: January 21, 2025
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
  • Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof
    Patent number: 11746155
    Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: September 5, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
  • ANTI-ADGRE2 ANTIBODIES AND USES THEREOF
    Publication number: 20230018888
    Abstract: Antibodies, fragments thereof and fusion proteins that specifically bind to ADGRE2, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including, for example, acute myeloid leukemia.
    Type: Application
    Filed: April 25, 2022
    Publication date: January 19, 2023
    Inventors: Antara Banerjee, Xingyue He, Shawn Jennings
  • CANNABINOID RECEPTOR TYPE 1 (CB1) BINDING PROTEINS AND USES THEREOF
    Publication number: 20220396620
    Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
    Type: Application
    Filed: April 29, 2019
    Publication date: December 15, 2022
    Inventors: Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
  • CANNABINOID RECEPTOR TYPE 1 (CB1) BINDING PROTEINS AND USES THEREOF
    Publication number: 20210198358
    Abstract: The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
    Type: Application
    Filed: March 16, 2021
    Publication date: July 1, 2021
    Inventors: Antara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
  • MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS
    Publication number: 20140037627
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat S. aureus infection, in particular, S. aureus infections of the lungs. Also provided are use agonists and antagonists of PILR? and PILR?, respectively, to prevent such infections.
    Type: Application
    Filed: August 8, 2013
    Publication date: February 6, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Antara Banerjee, Paul G. Heyworth
  • MODULATION OF PILR RECEPTORS TO TREAT SEPSIS
    Publication number: 20130323239
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILR? and PILR?, respectively, to prevent the development of sepsis.
    Type: Application
    Filed: August 8, 2013
    Publication date: December 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Antara Banerjee, Paul G. Heyworth
  • MODULATION OF PILR RECEPTORS TO TREAT MICROBIAL INFECTIONS
    Publication number: 20120128673
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat S. aureus infection, in particular, S. aureus infections of the lungs. Also provided are use agonists and antagonists of PILR? and PILR?, respectively, to prevent such infections.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 24, 2012
    Applicant: Schering Corporation
    Inventors: Antara Banerjee, Paul G. Heyworth
  • MODULATION OF PILR RECEPTORS TO TREAT SEPSIS
    Publication number: 20120121588
    Abstract: The present invention provides methods of using agonists and antagonists of PILR? and PILR?, respectively, to treat immune mediated sepsis. Also provided are methods of prophylactically treating with agonists and antagonists of PILR? and PILR? respectively, to prevent the development of sepsis.
    Type: Application
    Filed: May 14, 2010
    Publication date: May 17, 2012
    Applicant: SCHERING CORPORATION
    Inventors: Antara Banerjee, Paul G. Heyworth